CD22 and neoplasm: AuLtNps exhibited a proinflammatory cytokine secretion profile with increases in CD3, CD8+ T, and CD4+ T cells, as well as an increase in the proportion of CD22+ cells, suggesting that nanoparticles obtained using tumor lysate as a reducing agent activate both humoral and cellular immunity.